Small molecule αv integrin antagonists: novel anticancer agents

Bibliography

• RUOSLAHTI E, PIERSCHBACHER M: Arg-Gly-Asp: A versatile cell recognition sequence. Cell (1986) 44:517–518.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• CHERESH D: Integrins: structure, function and biological properties. Adv. Mole. Cell Biol. (1993) 6:225–252.
   Google Scholar
• KORNBERG U, EARP HS, TURNER CE et al.: Signaltransduction by integrins: Increased protein tyrosine phosphorylation caused by clustering of pi integrins. Proc. Natl. Acad. Sci. USA (1991) 88:8392–8395.
   PubMed Web of Science ®Google Scholar
• KORNBERG L, EARP HS, PARSONS JT et al.: Cell adhesionor integrin clustering increased phorphorylation of a focal adhesion associated kinase. J. Biol. Chem. (1992) 117:1101–1107.
   Google Scholar
• GUAN JL, SHALLO WAY D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature (1992) 358:690–692.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MA, CRAGOE EJ, LECHENE CP: pH regulationin spread and round cells. J. Biol. Chem. (1990) 265:1327–1332.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MA, LECHENE C, INGBER DE: Insolublefibronectin activates the Na+/H antiporter by clustering and immobilizing integrin cc301, independent of cell shape. Proc. Natl. Acad. Sci. USA (1991) 88:7849–7853.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ M, LECHENE C: Adhesion is required forprotein kinase C dependent activation of the Na+/H+ antiporter by platelet-derived growth factor. Proc. Natl. Acad. Sci. USA (1992) 89:6138–6141.
   PubMed Web of Science ®Google Scholar
• PELLETIER AJ, BODARY SC, LEVINSON AD: Signal transduction by the platelet integrin am433: induction of calcium oscillations required for protein-tyrosine phosphorylation and ligand-induced spreading of stably transfected cells. Mol. Biol. Cell .(1992) 3:989–998.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MA: Spreading of human endothelial cellson fibronectin or vitronectin triggers elevation of intracellular free calcium. J. Cell. Biol. (1992) 120:1003–1010.
   Web of Science ®Google Scholar
• LEAVESLEY DI, SCHWARTZ MA, ROSENFELD M, CHERESH DA: Integrin 131- and 03-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell. Biol. (1993) 121:163–170.
   PubMed Web of Science ®Google Scholar
• MCNAMEE HP, INGBER DE, SCHWARTZ M: Adhesion to fibronectin stimulates inositol lipid synthesis and enhances PDGF-induced inositol lipid breakdown. J. Cell. Biol. (1993) 121:673–678.
   PubMed Web of Science ®Google Scholar
• GUADAGNO TM, OHTSUBO M, ROBERTS JM et al.: A link between cyclin A expression and adhesion dependent cell cycle proliferation. Science (1993) 262:1572–1575.
   PubMed Web of Science ®Google Scholar
• VARNER JA, EMERSON D, JULIANO R: Integrin a301 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol. Biol. Cell (1995) 6:725–740.
   PubMed Web of Science ®Google Scholar
• APLINE AE, HOWE A, ALAHARI SK, JULIANO RL: Signaltransduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules and selectins. Pharmacol. Rev. (1998) 50:197–263.
   PubMed Web of Science ®Google Scholar
• MEREDITH JE, FAZELI B, SCHWARTZ M: The extracel-lular matrix as a cell survival factor. Mol. Biol. Cell (1993) 4:953–961.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY AMP, REISFELD RA, CHERESH DA: Integrin avi33 rescues melanoma cells from apoptosis in a three dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91:8856–8860.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin av133 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 749:1157–1164.
   Web of Science ®Google Scholar
• •Paper illustrating avf33 ligand is necessary for cell survival.
   Google Scholar
• PFAFF M, TANGEMANN K, MULLER B et al.: Selective recognition of cyclic RGD peptides of NMR defined conformation by ccm433, ccv133 and a301 integrins. J. Biol. Chem. (1994) 269:20233–20238
   PubMed Web of Science ®Google Scholar
• HEALY J, MURAYAMA O, MAEDA T et al.: Peptide ligands for integrin avOi selected from random phage display libraries. Biochemistry (1995) 34:3948–3955.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN E, GAY DA, RUOSLAHTI E: Selection of peptides binding to the cc301 integrin from a phage display library. J. Biol. Chem. (1993) 268:20205–20210.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN E, WANG B, RUOSLAHTI E: Isolation of a highly specific ligand for the a301 integrin from a phage display library. J. Cell. Biol. (1994) 124:373–380.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: RGD and other recognition sequences for integrins. Ann. Rev. Cell. Dev. Biol. (1996) 12:697–715.
   PubMed Web of Science ®Google Scholar
• CHERESH D: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA (1987) 84:6471–6475.
   PubMed Web of Science ®Google Scholar
• LEAVESLEY DI, FERGUSON GD, WAYNER EA et al.: Requirement of integrin 03 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell. Biol. (1992) 117:1101–1107.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, MATHIAS P, CHERESH DA et al.: IntegrinsavP3 and av03 promote adenovirus internalization but not virus attachment. Cell (1993) 73:309–319.
   PubMed Web of Science ®Google Scholar
• BREM RB, ROBBINS SG, WILSON DJ et al.: Inimunolocal-ization of integrins in the human retina. Invest. Ophthal. Vis. Sci. (1994) 35:3466–3474.
   PubMed Web of Science ®Google Scholar
• LESSEY BA, CASTELBAUM AJ, SAWIN SW et al.: Aberrant integrin expression in endometrium of women with endometriosis. J. Clin. Endocr.Metab. (1994) 79:643–649.
   PubMed Web of Science ®Google Scholar
• SATO M, SARDANA MK, GRASSER WA et al.: Echistatin is a potent inhibitor of bone resorption in culture. J. Cell. Biol. (1990) 111:1713–1723.
   PubMed Web of Science ®Google Scholar
• HORTON MA, TAYLOR ML, ARNETT TR et al.: Arg-Gly-Asp(RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. (1991) 195:368–375.
   PubMed Web of Science ®Google Scholar
• HARTMAN GD, DUGGAN ME: cc,133 Integrin antagonists as inhibitors of bone resorption. Exp. Opin. Invest. Drugs (2000) (In press).
   Google Scholar
• GLADSON C, CHERESH D: Glioblastoma expression of vitronectin and the ccv133 integrin. J. Clin. Invest. (1991) 88:1924–1932.
   PubMed Web of Science ®Google Scholar
• LIAPIS H, ADLER LM, WICK MR et al.: Expression of av p?integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human Path. (1997) 28:443–449.
   PubMed Web of Science ®Google Scholar
• SEFTOR R, SEFTOR E, GEHLSEN KR et al.: Role of the avP3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA (1992) 89:1557–1561.
   PubMed Web of Science ®Google Scholar
• •Signal transduction through a„f33 elevation of MMP expression.
   Google Scholar
• NIP J, SHIBATA H, LOSKUTOFF D et al.: Human melanoma cells derived from lymphatic metastases use integrin a133 to adhere to lymph node vitronectin. J. Clin. Invest. (1992) 90:1406–1413.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, METTE SA, ELDER DE et al.: Integrin distri-bution in malignant melanoma: association of the p3 subunit with tumor progression. Cancer Res. (1990) 50:6757–6764.
   PubMed Web of Science ®Google Scholar
• •03 integrin important in tumour invasiveness.
   Google Scholar
• HIEKEN, TJ, FAROLAN M, RONAN SG et al.: 133 integrin expression in melanoma predicts subsequent metastasis. J. Surg. Res. (1996) 63:169–173.
   PubMed Web of Science ®Google Scholar
• GASPARINI G, BROOKS PC, BIGANZOLI E et al.: Vascular integrin av133: A new prognostic indicator in breast cancer. Clin. Cancer Res. (1998) 4:2625–2634.
   PubMed Web of Science ®Google Scholar
• MORETTI S, MARTINI L, BERTI E et al.: Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. (1993) 3:235–239.
   PubMed Web of Science ®Google Scholar
• SCHADENDORF D, GAWLIK C, HANEY U et al.: Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors. J. Pathol. (1993) 170:429–434.
   PubMed Web of Science ®Google Scholar
• DANEN EH, JANSEN KF, VAN KRAATS AA et al.: Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progres-sion in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer (1995) 61:491–496.
   Google Scholar
• FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA et al.: Involvement of integrin av gene expression in human melanoma tumorigenicity. J. Clin. Invest. (1992) 89:2018–2022.
   PubMed Web of Science ®Google Scholar
• SANDERS LC, FELDING-HABERMANN B, MUELLER BM et al.: Role of av integrins and vitronectin in human melanoma cell growth. Cold Spring Harbor Symposia on Quantitative Biology LVII (1992) 58:233–240.
   Google Scholar
• NIP J, BRODT P: The role of the integrin vitronectin receptor av133 in melanoma metastasis. Cancer Metastasis Rev. (1995) 14:241–252.
   PubMed Web of Science ®Google Scholar
• FILARDO EJ, BROOKS PC, DEMING SL eta/.: Requirement of the NPXY motif in the integrin 133 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell. Biol. (1995) 130:441–450.
   Google Scholar
• SOLDI R, STEFANIA M, STRASLY M et al.: Role of avP3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO (1999) 18:882–903.
   PubMed Web of Science ®Google Scholar
• STROMBLAD S, BECKER JC, YEBRA M et al.: Suppression of p53 activity and p21 WAF/CIP1 expression by vascular cell integrin av133 during angiogenesis. J. Clin. Invest. (1996) 98:426–433.
   PubMed Web of Science ®Google Scholar
• SCANTENA M, ALMEIDA M, CHAISSON ML et al.: NFIc13 mediates a1133 integrin- induced endothelial cell survival. J. Cell. Biol. (1998) 141:1083–1093.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, SANDERS LC et al.: Localiza-tion of matrix metalloproteinase MAIP-2 to the surface of invasive cells by interaction with integrin avi33. Cell (1996) 85:683–693.
   PubMed Web of Science ®Google Scholar
• DERYUGINA El, BOURDON MA, JUNGWIRTH K et al.:Functional activation of integrin av133 in tumor cells expressing membrane-type 1 matrix metalloprote-inase. Int. J. Cancer (2000) 86:15–23.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R et al.: Anti-integrin av133 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815–1822.
   PubMed Web of Science ®Google Scholar
• • Avf33 antagonists may be an anti-angiogenic approach for human breast cancer treatment.
   Google Scholar
• BROOKS PC, CLARK RAF, CHERESH DA: Requirement ofvascular integrin av133 for angiogenesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• MCLEAN JW, VESTAL DJ, CHERESH DA, BODARY SC:cDNA sequence of the human integrin beta 5 subunit. J. Biol. Chem. (1990) 256:17126–17131.
   Google Scholar
• RAMASWANY H, HEMLER ME: Cloning, primary structure and properties of a novel human integrin subunit. EMBO (1990) 9:1561–1568.
   PubMed Web of Science ®Google Scholar
• LEWIS JM, CHERESH DA, SCHWARTZ MA: Protein kinase C regulates alpha v beta dependent cytoskeletal associations and focal adhesion kinase phosphoryla-don. J. Cell. Biol. (1996) 134:1323–1332.
   PubMed Web of Science ®Google Scholar
• KLEMKE RL, YEBRA M, BAYNA E et al.: Receptor tyrosine kinase signaling required for integrin avf35 directed cell motility but not adhesion on vitronectin. J. Cell. Biol. (1994) 127:859–866.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER R et al.: Defini-tion of two angiogenic pathways by distinct av integrins. Science (1995) 27:1500–1502.
   Google Scholar
• •Two signalling pathways described.
   Google Scholar
• ENENSTEIN J, WALEH NS, KRAMER RH: Basic FGF and TGF 13 differentially modulate integrin expression of human microvascular endothelial cells. Exp. Cell Res. (1992) 203:499–503.
   PubMed Web of Science ®Google Scholar
• KRISSANSON GW, ELLIOT MJ, LUCAS CM eta/.: Identifica-tion of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. J. Biol. Chem. (1990) 265:823–830.
   Google Scholar
• MEDHORA M, TEITELBAUM S, CHAPPEL J et al.: la, 25-dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin ccv133. J. Biol. Chem. (1993) 268:1456–1461.
   PubMed Web of Science ®Google Scholar
• GAO X, ROSS FP, ZHANG L et al.: Cloning of thepromoter for the avian integrin 133 subunit gene and its regulation by 1,25-dihydroxyvitarnin D3. J. Biol. Chem. (1993) 268:27371–27380.
   PubMed Web of Science ®Google Scholar
• WERNERT N, RAES MB, LASSALLE P et al.: c-ets 1 protoon-cogene is a transcription factor expressed in endothe-lial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. (1992) 140:119–127.
   PubMed Web of Science ®Google Scholar
• ODA N, ABE M, SATO Y: ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expres-sion of matrix metalloproteinases and integrin 133. J. Cell Physiol. (1999) 178:121–132.
   PubMed Web of Science ®Google Scholar
• GLADSON CL: Expression of alpha v beta 3 in small blood vessels of g,lioblastoma tumors. J. Neuropathol. E. Neurol. (1996) 55:1143–1149.
   PubMed Web of Science ®Google Scholar
• LEENI K, REIDAR G, JYRKI H, HANNU L: Integrins alpha5betal, alphavbetal and alphavbeta6 collabo-rate in squamous carcinoma cell spreading and migration on fibronectin. Exp. Cell Res. (2000) 255:10–17.
   PubMedGoogle Scholar
• MOYLE M, NPAIER MA, MCLEAN JW: Cloning and expres-sion of a divergent integrin subunit beta 8./ Biol. Chem. (1991) 266:19650–19658.
   PubMed Web of Science ®Google Scholar
• NISHIMURA SL, SHEPPARD D, PYTELA R: Integrin alpha v beta 8. Interaction with vitronectin and functional divergence of the beta 8 cytoplasmic domain. J. Biol. Chem. (1994) 269:28708–28715.
   Google Scholar
• AGREZ M, CHEN A, CONE RI, PYTELA R, SHEPPARD D: The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. Cell. Biol. (1994) 127:547–556.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA, CHERESH DA: Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. J. Clin. Invest. (1992) 89:2018–2022.
   PubMed Web of Science ®Google Scholar
• PETITCLERC E, STROMBLAD S, VON SCHALSCHA TL et al.:Integrin alpha (v) beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. (1999) 59:2724–2730.
   Google Scholar
• MITJANS F, SANDER D, ADAN J et al.: An anti-alphav-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J. Cell. Sci. (1995) 108:2825–2838.
   PubMed Web of Science ®Google Scholar
• BADER BL, RAYBURN H, CROWLEY D, HYNES RO.: Extensive vasculogenesis, angiogenesis and organo-genesis precede lethality in mice lacking all av integrins. Cell (1998) 95:507–519.
   Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanism of the angiogenic switch during tumorige-nesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• HOLMGREN LM, O'REILLY MS, FOLKMAN J: Dormancy of micrometatses: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. (1995) 1:149–153.
   PubMed Web of Science ®Google Scholar
• •A seminal paper.
   Google Scholar
• PARANGI S, O'REILLY MS, CHRISTOFORI G et al.: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA (1996) 93:2002–2007.
   PubMedGoogle Scholar
• RABB H: avi33 and av133 integrin distribution in neoplastic kidney. Am. J. Nephrol. (1996) 16:402–408.
   PubMed Web of Science ®Google Scholar
• MAX R, GERRITSEN R, NOOIJEN P et al.: Immunohisto-chemical analysis of integrin avi33 expression on tumor-associated vessels of human carcinomas. Int. J. Cancer (1997) 71:320–324.
   PubMed Web of Science ®Google Scholar
• CLARK RAF, TONNESEN MG, GAILIT J et al.: Transientfunctional expression of av133 on vascular cells during wound repair. Am. J. Pathol. (1996) 148:1407–1421.
   PubMed Web of Science ®Google Scholar
• ENENSTEIN J, KRAMER RH: Confocal microscopic analysis of integrin expression on the microvascula-ture and its sprouts in the neonatal foreskin. J. Invest. Dermatol. (1994) 103:381–386.
   PubMed Web of Science ®Google Scholar
• CHRISTOFIDOU-SOLOMIDOU M, BRIDGES M, MURPHY et al.: Expression and function of endothelial cell av integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am. J. Pathol. (1997) 151:975–983.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, THEESFELD C, SUGITA M et al.: Involve-ment of integrin av133 and av133 in ocular neovascualar diseases. Proc. Natl. Acad. Sci. USA (1996) 93:9764–9769.
   PubMed Web of Science ®Google Scholar
• SEPP NT, LI L-J, LEE KH et al.: Basic fibroblast growth factor increases expression of the avi33 complex on human microvessel endothelial cells. J. Invest. Dermatol. (1994) 103:295–299.
   PubMed Web of Science ®Google Scholar
• KERR JS, WEXLER RS, MOUSA SA et al.: Novel small molecule av integrin antagonists: Comparative anticancer efficacy with known angiogenesis inhibi-tors. AntiCancer Res. (1999) 19:959–968.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science (1998) 279:377–380.
   PubMed Web of Science ®Google Scholar
• DENARDO SJ, BURKE PA, LEIGH BR et al.: Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioirnmunotherapy. Cancer Biother. Radiopharm. (2000) 15:71–79.
   PubMed Web of Science ®Google Scholar
• LODE HN, MOEHLER T, XIANG R et al.: Synergy between a antiangiogenic integrin av antagonist and an antibody-cytokine fusion protein eradicates sponta-neous tumor metastases. Proc. Natl. Acad. Sci. USA (1999) 96:1591–1596.
   PubMed Web of Science ®Google Scholar
• LUNA J, TOBE T, MOUSA SA et al.: Antagonists of a433 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563–573.
   PubMed Web of Science ®Google Scholar
• ERDREICH-EPSTEIN A, SHIMADA H, GROSHEN S et al.:Integrins av133 and avp3 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. (2000) 60:712–721.
   PubMed Web of Science ®Google Scholar
• GURRATH M, MULLER G, KESSLER H et al.: Conformation-actvity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. (1992) 210:911–921.
   PubMedGoogle Scholar
• PIERSHBACHER MD, RUOSLAHTI E: Influence of sterochemistry of the sequence Arg-Gly-Asp-liaa on binding specificity in cell adhesion./ Biol. Chem. (1987) 262:17294–17298.
   PubMed Web of Science ®Google Scholar
• BACH AC, ESPINA JR, JACKSON SA et al.: Type II to Type lb-turn swap changes specificity for integrins. J. Am. Chem. Soc. (1996) 118:293–294.
   Web of Science ®Google Scholar
• KEENAN RM, MILLER WH, KWON C et al.: Discovery of potent non-peptide vitronectin (avp3 integrin) antago-nists. J. Med. Chem. (1997) 40:2289–2292.
   PubMed Web of Science ®Google Scholar
• CORBETT JW, GRACIANI NR, MOUSA SA, DEGRADO WF: Solid phase synthesis of a selective av133 integrin antagonist library. Bioorganic Med. Chem. Lea. (1997) 7:1371–1376.
   Web of Science ®Google Scholar
• KNOLLE J, BREIPHOL G, GUBA W et al.: Design and synthesis of potent and selective peptidomimetic vitronectin receptor antagonists. In: Peptide Chemistry. Structure and Biological Proceedings. 15th American Peptide Symp. Tam JP, Kaumaya TP (Eds.) Mayflower Scientific Ltd, UK (1997):102.
   Google Scholar
• CARRON CP, MEYER DM, PEGG JA et al.: A peptidomi-metic antagonist of the integrin alpha(v) beta3 inhibits Leydig cell tumor growth and the develop-ment of hypercakemia of malignancy. Cancer Res. (1998) 58:1930–1935.
   PubMed Web of Science ®Google Scholar
• GOULD RJ, POLOKOFF MA, FRIEDMAN PA et al.: Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med. (1990) 195:168–171.
   PubMed Web of Science ®Google Scholar
• •One of the first descriptions of disintegrins.
   Google Scholar
• NIEWIAROWSKI S, MCLANE MA, KLOCZEWIAK M, STEWART GJ: Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Semin. Hematol. (1994) 31:289–300.
   PubMed Web of Science ®Google Scholar
• BEVIGLIA L, STEWART GJ, NIEWIAROWSKI S: Effect offour disintegrins on the adhesive and metastatic properties of B6F10 melanoma cells in a murine model. Oncol. Res. (1995) 7:7–20.
   PubMed Web of Science ®Google Scholar
• WIERZBICKA-PATYNOWSKI I, NIEWIAROWSKI S, MARCINKIEWICZ C et al.: Structural requirements of echistatin for the recognition of av33 and a5Pi integrins. J. Biol. Chem. (1999) 274:37809–37814.
   PubMed Web of Science ®Google Scholar
• VAZQUES F, HASTINGS G, ORTEGA M-A et al.: METH-1, a human ortholog of ADAMTS-1 and METH-2 are members of a new family of proteins with angio-inhibitory activity./ Biol. Chem. (1999) 274:23349–23357.
   Google Scholar
• •Possible new gene family of inhibitors of angiogenesis.
   Google Scholar
• PITTS WJ, WITYAK J, SMALLHEER JM et al.: Isoxazolines as potent antagonists of the integrin av133.J. Med. Chem. (2000) 43:27–40.
   Google Scholar
• BATT DG, PETRAITIS JJ, HOUGHTON GC et al.: Disubsti-tuted indazoles as potent antagonists of the integrin a33. J. Med. Chem. (2000) 43:41–58.
   PubMed Web of Science ®Google Scholar
• MILLER WH, ALBERTS DP, BHATNAGAR PK et al.: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic. J. Med. Chem. (2000) 43:22–26.
   PubMed Web of Science ®Google Scholar
• ALLMAN R, COWBURN P, MASON M: In vitro and in vivo effects of a cyclic peptide with affinity for the avI33 intgrin in human melanoma cells. Eur. J. Cancer (2000) 36:410–422.
   PubMed Web of Science ®Google Scholar
• HOEKSTRA WJ, POULTER BL: Combinatorial chemistry techniques applied to nonpeptide integrin antago-nists. Curr. Med. Chem. (1998) 5:195–204.
   PubMed Web of Science ®Google Scholar
• PASCO S, HAN J, GILLERY P et al.: A specific sequence of the non-collagenous domain of the a(IV) chain of Type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res. (2000) 60:467–473.
   PubMed Web of Science ®Google Scholar
• ALBINI A, NOONAN D, SANTI L: Angiogenesis at the interface between basic and clinical research. Int. J. Biol. Markers (1999) 14:202–206.
   PubMed Web of Science ®Google Scholar
• HAUBNER R, WESTER H-J, REUNING U et al.: Radiola-beled avp3 integrin antagonists: A new class of tracers for tumor targeting./ Nuclear Med.(1999) 40:1061–1071.
   PubMed Web of Science ®Google Scholar
• •First radiolabelled avf33 antagonist.
   Google Scholar
• SIVOLAPENKO GB, SKARLOS D, PECTASIDES D et al.: Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing syntheic peptide. Eur. J. Nuclear Med. (1998) 25:1383–1389.
   PubMedGoogle Scholar
• SIPKINS DA, CHERESH DA, KAZEMI MR et al.: Detection of tumor angiogenesis in vivo by a3-targeted magnetic resonance imaging. Nature Med. (1998) 4:623–626.
   PubMed Web of Science ®Google Scholar
• •Non-invasive way to assess growth and phenotype of tumours.
   Google Scholar
• KLOHS WD, HAMBY JM: Antiangiogenic agents. Pharm. Biotech. (1999)10:544–549.
   Google Scholar
• •Good review.
   Google Scholar